440 related articles for article (PubMed ID: 26318099)
1. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs).
Rickli A; Luethi D; Reinisch J; Buchy D; Hoener MC; Liechti ME
Neuropharmacology; 2015 Dec; 99():546-53. PubMed ID: 26318099
[TBL] [Abstract][Full Text] [Related]
2. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs).
Luethi D; Trachsel D; Hoener MC; Liechti ME
Neuropharmacology; 2018 May; 134(Pt A):141-148. PubMed ID: 28720478
[TBL] [Abstract][Full Text] [Related]
3. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT
Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Johnson RA; Janowsky A
Biochem Pharmacol; 2018 Dec; 158():27-34. PubMed ID: 30261175
[TBL] [Abstract][Full Text] [Related]
4. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.
Eshleman AJ; Forster MJ; Wolfrum KM; Johnson RA; Janowsky A; Gatch MB
Psychopharmacology (Berl); 2014 Mar; 231(5):875-88. PubMed ID: 24142203
[TBL] [Abstract][Full Text] [Related]
6. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.
Elmore JS; Decker AM; Sulima A; Rice KC; Partilla JS; Blough BE; Baumann MH
Neuropharmacology; 2018 Nov; 142():240-250. PubMed ID: 29501528
[TBL] [Abstract][Full Text] [Related]
7. Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines.
Kolaczynska KE; Luethi D; Trachsel D; Hoener MC; Liechti ME
Front Pharmacol; 2019; 10():1423. PubMed ID: 31849671
[No Abstract] [Full Text] [Related]
8. Monoamine receptor interaction profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI derivatives).
Luethi D; Widmer R; Trachsel D; Hoener MC; Liechti ME
Eur J Pharmacol; 2019 Jul; 855():103-111. PubMed ID: 31063768
[TBL] [Abstract][Full Text] [Related]
9. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
[TBL] [Abstract][Full Text] [Related]
10. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats.
Fantegrossi WE; Harrington AW; Eckler JR; Arshad S; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
Psychopharmacology (Berl); 2005 Sep; 181(3):496-503. PubMed ID: 15983786
[TBL] [Abstract][Full Text] [Related]
11. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity.
Monte AP; Marona-Lewicka D; Lewis MM; Mailman RB; Wainscott DB; Nelson DL; Nichols DE
J Med Chem; 1998 Jun; 41(12):2134-45. PubMed ID: 9622555
[TBL] [Abstract][Full Text] [Related]
12. Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines.
Kolaczynska KE; Luethi D; Trachsel D; Hoener MC; Liechti ME
Front Pharmacol; 2021; 12():794254. PubMed ID: 35222010
[TBL] [Abstract][Full Text] [Related]
13. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
Moya PR; Berg KA; Gutiérrez-Hernandez MA; Sáez-Briones P; Reyes-Parada M; Cassels BK; Clarke WP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1054-61. PubMed ID: 17337633
[TBL] [Abstract][Full Text] [Related]
14. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.
Kamińska K; Świt P; Malek K
J Anal Toxicol; 2021 Jan; 44(9):947-956. PubMed ID: 32128596
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT
Åstrand A; Guerrieri D; Vikingsson S; Kronstrand R; Green H
Forensic Sci Int; 2020 Dec; 317():110553. PubMed ID: 33160102
[TBL] [Abstract][Full Text] [Related]
16. Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.
Herian M; Wojtas A; Sobocińska MK; Skawski M; González-Marín A; Gołembiowska K
Pharmacol Rep; 2020 Dec; 72(6):1593-1603. PubMed ID: 33174181
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1.
Simmler LD; Buchy D; Chaboz S; Hoener MC; Liechti ME
J Pharmacol Exp Ther; 2016 Apr; 357(1):134-44. PubMed ID: 26791601
[TBL] [Abstract][Full Text] [Related]
18. Effect of
Tirri M; Bilel S; Arfè R; Corli G; Marchetti B; Bernardi T; Boccuto F; Serpelloni G; Botrè F; De-Giorgio F; Golembiowska K; Marti M
Front Psychiatry; 2022; 13():875722. PubMed ID: 35530025
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.
Halberstadt AL
Curr Top Behav Neurosci; 2017; 32():283-311. PubMed ID: 28097528
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of novel psychoactive benzofurans.
Rickli A; Kopf S; Hoener MC; Liechti ME
Br J Pharmacol; 2015 Jul; 172(13):3412-25. PubMed ID: 25765500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
